Table 3.
Nine cases of severe late complications
| Patient (age/sex) | Treatment site | Elapsed time (months) | SBRT dose schedule (total dose/fraction) | Response | Cumulative BED10 (Gy) | Late toxicity (RTOG late toxicity grade) |
|---|---|---|---|---|---|---|
| 31/M |
NPC, Lt. skull base |
24.4 |
21/3 |
CR |
101.5 |
Pontine necrosis (G5*) |
| 48/M |
NPC, Lt. skull base |
8.5 |
21/3 |
PR |
105.8 |
Lt. base of skull bone and soft tissue necrosis (G4) |
| 48/M |
NPC, Rt. skull base |
25.9 |
25/5 |
CR |
107.6 |
Pontine necrosis (G3) |
| 48/M |
NPC, Lt. skull base |
4.4, 6.8 |
21/3 |
CR |
118.5 |
Lt. nasopharyngeal wall soft tissue necrosis (G4), temporal lobe necrosis (G3) |
| 55/M |
SCC, Rt. BOT |
15.8 |
16/2 |
CR |
94.6 |
Mucosal ulcer and necrosis (G4) |
| 82/M |
SCC, Lt. BOT |
20.9 |
24/3 |
CR |
96.3 |
Unhealing mucosal ulcer and bleeding (G4) |
| 36/F |
ACC, Rt. lacrimal gland |
30.0, 32.4, 30 |
25/5 |
CR |
90.6 |
Radiation retinopathy (G3), temporal lobe necrosis (G3), NVG (G3) |
| 41/F |
ACC, Lt. lacrimal gland |
28.5, 28.5 |
20/5 |
CR |
87.5 |
Radiation retinopathy (G3), NVG (G3) |
| 59/M | ACC, Rt. orbit | 15.1 | 25/5 | CR | 90.6 | Optic neuropathy (G3) |
*Pontine necrosis was the definite cause of death
SBRT, stereotactic body radiotherapy; BED10, biologically equivalent dose in α/β ratio of 10; M, male; NPC, nasopharyngeal carcinoma; CR, complete response; PR, partial response; SCC, squamous cell carcinoma; BOT, base of tongue; F, female; ACC, adenoid cystic carcinoma; NVG, neovascular glaucoma.